Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma
1. Patients with B-cell non-Hodgkin’s lymphoma receiving tisagenlecleucel did not show delayed lymphoma progression compared to those receiving standard salvage therapy. 2. Tisagenlecl...